Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CELZ Stock Summary
Top 10 Correlated ETFs
CELZ
In the News
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
3 Methods for Finding Penny Stocks to Buy and Hold
Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Creative Medical (CELZ) Stock Up 121% Today?
Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial. That clearance comes from the FDA and covers CELZ-201 cell therapy.
Penny Stocks To Buy Now? 5 To Watch After News This Week
Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?
Penny Stocks to Watch as June Comes to an End
Are these penny stocks on your watchlist right now? The post Penny Stocks to Watch as June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now
Short squeeze penny stocks to watch. The post Penny Stocks To Buy?
Best Penny Stocks To Buy Now? 5 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch right now. The post Best Penny Stocks To Buy Now?
Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April
Check these three trending penny stocks out for your watchlist right now The post Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
CELZ Financial details
CELZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 80.03 | 2.84 | 0.27 | 0.08 | 0.01 | |
Net income per share | -5.02K | -648.1 | 45.97 | -9.21 | -3.76 | |
Operating cash flow per share | -586.6 | -7.5 | -6.82 | -7.15 | -5.7 | |
Free cash flow per share | -586.6 | -11.81 | -6.82 | -7.15 | -5.7 | |
Cash per share | 42.87 | 1.69 | 33.01 | 26.11 | 2.46 | |
Book value per share | -3.9K | -686.9 | 31.45 | 14.54 | 7.35 | |
Tangible book value per share | -4.11K | -697.59 | 29.83 | 14.15 | 7.35 | |
Share holders equity per share | -3.9K | -686.9 | 31.45 | 14.54 | 7.35 | |
Interest debt per share | 1.43K | 34.83 | 13.17 | -0.09 | 0 | |
Market cap | 465.3K | 8.05M | 7.18M | 4.16M | 6.49M | |
Enterprise value | 1.44M | 8.75M | -3.54M | -14.24M | 3.02M | |
P/E ratio | -0.04 | -0.21 | 0.48 | -0.41 | -1.23 | |
Price to sales ratio | 2.81 | 48.96 | 81.81 | 46.91 | 721.02 | |
POCF ratio | -0.38 | -18.53 | -3.24 | -0.53 | -0.81 | |
PFCF ratio | -0.38 | -11.77 | -3.24 | -0.53 | -0.81 | |
P/B Ratio | -0.06 | -0.2 | 0.7 | 0.26 | 0.63 | |
PTB ratio | -0.06 | -0.2 | 0.7 | 0.26 | 0.63 | |
EV to sales | 8.69 | 53.16 | -40.39 | -160.76 | 335.81 | |
Enterprise value over EBITDA | -1.3 | -8.34 | 1.17 | 1.42 | -0.55 | |
EV to operating cash flow | -1.19 | -20.12 | 1.6 | 1.83 | -0.38 | |
EV to free cash flow | -1.19 | -12.77 | 1.6 | 1.83 | -0.38 | |
Earnings yield | -22.31 | -4.66 | 2.08 | -2.42 | -0.81 | |
Free cash flow yield | -2.61 | -0.08 | -0.31 | -1.88 | -1.24 | |
Debt to equity | -0.13 | -0.02 | 0 | 0 | 0 | |
Debt to assets | 2 | 1.1 | 0 | 0 | 0 | |
Net debt to EBITDA | -0.88 | -0.66 | 3.53 | 1.83 | 0.63 | |
Current ratio | 0.01 | 0 | 10.22 | 5.64 | 27.65 | |
Interest coverage | -0.6 | -0.91 | -0.73 | 102.11 | 0 | |
Income quality | 0.14 | 0.01 | -0.12 | 0.77 | 1.52 | |
Dividend Yield | 0 | 0 | 0.67 | 0 | 0 | |
Payout ratio | 0 | 0 | 0.32 | 0 | 0 | |
Sales general and administrative to revenue | 7.39 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 1.24 | 70.75 | 218.96 | |
Intangibles to total assets | 0.82 | 0.86 | 0.05 | 0.02 | 0 | |
Capex to operating cash flow | 0 | 0.58 | 0 | 0 | 0 | |
Capex to revenue | 0 | -1.52 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -3.74 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 1.04 | 6.78 | 0.78 | 4.07 | |
Graham number | 20.99K | 3.16K | 180.36 | 54.89 | 24.92 | |
ROIC | 0.2 | 0.03 | -0.24 | -0.64 | -0.53 | |
Return on tangible assets | -110.13 | -383.17 | 1.39 | -0.54 | -0.49 | |
Graham Net | -4.11K | -697.59 | 29.8 | 16.14 | 2.2 | |
Working capital | -8.51M | -40.42M | 9.69M | 15.43M | 9.9M | |
Tangible asset value | -8.51M | -40.42M | 9.69M | 15.43M | 10.34M | |
Net current asset value | -8.51M | -40.42M | 9.69M | 15.43M | 9.9M | |
Invested capital | -0.13 | -0.02 | 0 | 0 | 0 | |
Average receivables | 7.6K | 2.8K | 1.24K | -5.04M | -5.04M | |
Average payables | 326.31K | 335.84K | 556.38K | 2.01M | 1.79M | |
Average inventory | 0 | 0 | 5.43K | 10.53K | 8.39K | |
Days sales outstanding | 12.35 | 0 | 10.34 | -41.52K | 0 | |
Days payables outstanding | 2.57K | 2.53K | 5.8K | 41.86K | 32.17K | |
Days of inventory on hand | 0 | 0 | 82.71 | 130.6 | 668.56 | |
Receivables turnover | 29.55 | 0 | 35.31 | -0.01 | 0 | |
Payables turnover | 0.14 | 0.14 | 0.06 | 0.01 | 0.01 | |
Inventory turnover | 0 | 0 | 4.41 | 2.79 | 0.55 | |
ROE | 1.29 | 0.94 | 1.46 | -0.63 | -0.51 | |
Capex per share | 0 | -4.31 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.04 | 0.01 | 0 | 0 | 0 | |
Net income per share | -0.67 | -4.37 | -0.7 | -0.78 | -1.02 | |
Operating cash flow per share | -0.62 | -2.55 | -2.73 | -0.7 | -0.91 | |
Free cash flow per share | -0.62 | -2.55 | -2.73 | -0.7 | -0.91 | |
Cash per share | 19.25 | 20.23 | 10.34 | 9.63 | 8.37 | |
Book value per share | 15.73 | 11.27 | 10.53 | 9.74 | 8.45 | |
Tangible book value per share | 15.4 | 10.96 | 10.24 | 9.46 | 8.12 | |
Share holders equity per share | 15.73 | 11.27 | 10.53 | 9.74 | 8.45 | |
Interest debt per share | 0.03 | -0.04 | 0 | 0 | 0 | |
Market cap | 6.17M | 5.36M | 7.04M | 6.54M | 7.04M | |
Enterprise value | -15.82M | -13.04M | -2.48M | 2.55M | 2.54M | |
P/E ratio | -1.63 | -0.22 | -1.78 | -1.48 | -1.21 | |
Price to sales ratio | 112.27 | 288.34 | 0 | 0 | 1.17K | |
POCF ratio | -7.07 | -1.49 | -1.83 | -6.63 | -5.4 | |
PFCF ratio | -7.07 | -1.49 | -1.83 | -6.63 | -5.4 | |
P/B Ratio | 0.28 | 0.34 | 0.47 | 0.48 | 0.58 | |
PTB ratio | 0.28 | 0.34 | 0.47 | 0.48 | 0.58 | |
EV to sales | -287.56 | -700.87 | 0 | 0 | 422.58 | |
Enterprise value over EBITDA | 16.49 | 2.11 | 2.41 | -2.18 | -1.67 | |
EV to operating cash flow | 18.11 | 3.63 | 0.65 | -2.59 | -1.94 | |
EV to free cash flow | 18.11 | 3.63 | 0.65 | -2.59 | -1.94 | |
Earnings yield | -0.15 | -1.15 | -0.14 | -0.17 | -0.21 | |
Free cash flow yield | -0.14 | -0.67 | -0.55 | -0.15 | -0.19 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 22.92 | 2.97 | 9.25 | 3.41 | 2.96 | |
Current ratio | 55.44 | 5.64 | 36.35 | 34.46 | 28.6 | |
Interest coverage | -26.79 | 100.86 | -22.26K | 0 | 0 | |
Income quality | 0.89 | 0.58 | 3.65 | 0.9 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 4.2 | 288.61 | 0 | 0 | 165.45 | |
Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.17 | 0.49 | 0 | 0 | 1.53 | |
Graham number | 15.43 | 33.3 | 12.91 | 13.09 | 13.89 | |
ROIC | -0.04 | -0.39 | -0.07 | -0.09 | -0.13 | |
Return on tangible assets | -0.04 | -0.33 | -0.07 | -0.08 | -0.12 | |
Graham Net | 16.29 | 12.5 | 10.06 | 9.35 | 8.07 | |
Working capital | 21.61M | 15.43M | 14.41M | 13.34M | 11.62M | |
Tangible asset value | 21.61M | 15.43M | 14.41M | 13.34M | 11.63M | |
Net current asset value | 21.61M | 15.43M | 14.41M | 13.34M | 11.62M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | -2.51M | -7.55M | -5.04M | 0.5 | 0 | |
Average payables | 319.26K | 1.8M | 1.81M | 348.92K | 355.73K | |
Average inventory | 18.26K | 13.04K | 10.19K | 10.19K | 8.99K | |
Days sales outstanding | -8.22K | -48.77K | 0 | 0 | 0 | |
Days payables outstanding | 1.84K | 51.59K | 1.38K | 1.35K | 13.76K | |
Days of inventory on hand | 89.4 | 160.96 | 39.85 | 39.85 | 292.28 | |
Receivables turnover | -0.01 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.05 | 0 | 0.07 | 0.07 | 0.01 | |
Inventory turnover | 1.01 | 0.56 | 2.26 | 2.26 | 0.31 | |
ROE | -0.04 | -0.39 | -0.07 | -0.08 | -0.12 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CELZ Frequently Asked Questions
What is Creative Medical Technology Holdings, Inc. stock symbol ?
Creative Medical Technology Holdings, Inc. is a US stock , located in Phoenix of Az and trading under the symbol CELZ
What is Creative Medical Technology Holdings, Inc. stock quote today ?
Creative Medical Technology Holdings, Inc. stock price is $5.21 today.
Is Creative Medical Technology Holdings, Inc. stock public?
Yes, Creative Medical Technology Holdings, Inc. is a publicly traded company.